Fate Therapeutics Stock Forecast, Price & News

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

Is Fate Therapeutics a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Fate Therapeutics?

Wall Street analysts have given Fate Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fate Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Fate Therapeutics.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) released its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.52) by $0.06. The biopharmaceutical company earned $13.41 million during the quarter, compared to analyst estimates of $6.90 million. Fate Therapeutics had a negative net margin of 441.63% and a negative trailing twelve-month return on equity of 27.96%. The company's revenue was up 145.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.35) earnings per share.
View Fate Therapeutics' earnings history.

How has Fate Therapeutics' stock been impacted by COVID-19?

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 157.1% and is now trading at $61.16.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for FATE?

15 brokerages have issued 1 year price objectives for Fate Therapeutics' shares. Their forecasts range from $76.00 to $145.00. On average, they expect Fate Therapeutics' stock price to reach $111.00 in the next year. This suggests a possible upside of 81.5% from the stock's current price.
View analysts' price targets for Fate Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:

• J. Scott Wolchko, President, Chief Executive Officer & Director (LinkedIn Profile)
• Edward J. Dulac, Chief Financial Officer & Accounting Officer
• Bahram Valamehr, Chief Research & Development Officer (LinkedIn Profile)
• Wen Bo Wang, Senior Vice President-Technical Operations
• Yu Waye Chu, Senior Vice President-Clinical Development (LinkedIn Profile)

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Fate Therapeutics' key competitors?

Some companies that are related to Fate Therapeutics include Bio-Techne (TECH), Novozymes A/S (NVZMY), Repligen (RGEN), Novavax (NVAX), argenx (ARGX), QIAGEN (QGEN), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Vir Biotechnology (VIR), Halozyme Therapeutics (HALO) and Twist Bioscience (TWST).
View all of FATE's competitors.

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.95%), ARK Investment Management LLC (7.96%), BlackRock Inc. (6.93%), FMR LLC (6.78%), Price T Rowe Associates Inc. MD (3.27%) and Bellevue Group AG (2.75%). Company insiders that own Fate Therapeutics stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, Louis T Petrillo, Redmile Group, Llc and Yu-Waye Chu.
View institutional ownership trends for Fate Therapeutics.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Morgan Stanley, Morgan Stanley, Goldman Sachs Group Inc., Millennium Management LLC, Tekla Capital Management LLC, and Federated Hermes Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, Louis T Petrillo, and Yu-Waye Chu.
View insider buying and selling activity for Fate Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, JPMorgan Chase & Co., Deutsche Bank AG, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Amundi, Bellevue Group AG, and Invesco Ltd..
View insider buying and selling activity for Fate Therapeutics or or view top insider-buying stocks.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $61.16.

How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of $5.82 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-173,390,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 279 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Where are Fate Therapeutics' headquarters?

Fate Therapeutics is headquartered at 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at [email protected].